{"id":"absk021-with-fasted-state","_chembl":{"chemblId":"CHEMBL6068433","moleculeType":"Small molecule","molecularWeight":"474.95"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:51:52.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123388,"model":"claude-sonnet-4-5-20250929"},"description":"ABSK021 is an investigational drug being developed by Abbisko Therapeutics Co, Ltd, currently in Phase 1 clinical trials. The compound is being studied in a fasted state to evaluate its pharmacokinetic properties and safety profile. Limited information is publicly available regarding its molecular target or therapeutic indication.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT06186583","phase":"PHASE1","title":"A Mass Balance Study of [14C]ABSK021","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-12-13","conditions":"Healthy Subjects","enrollment":6},{"nctId":"NCT05280483","phase":"PHASE1","title":"ABSK021 Food Effect Study in Healthy Subjects","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2022-07-23","conditions":"Neoplasms","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ABSK021 with fasted state","genericName":"ABSK021 with fasted state","companyName":"Abbisko Therapeutics Co, Ltd","companyId":"abbisko-therapeutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABSK021, a small molecule, is a compound studied in a mass balance study involving healthy adult male Chinese subjects. The study, which was completed in 2023, investigated the pharmacokinetics of ABSK021 in both fed and fasted states.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}